Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.65 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.56 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.56 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.56 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.52 |
| ▸ | FEN1 | P39748 | 1/20 | 0.52 |
| ▸ | JAK2 | O60674 | 1/20 | 0.51 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.50 |
| ▸ | CES2 | O00748 | 1/20 | 0.48 |
| ▸ | CES1 | P23141 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | F2R | P25116 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 2/20 | 0.44 |
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | USP2 | O75604 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31004827 | 1.00 | TSHR (0.65) | TSHRTAS1R3TAS1R1TAS1R2ERCC5 | |
| SCHEMBL3781319 | 0.88 | TSHR (0.48) | TSHRTAS1R3TAS1R1TAS1R2ERCC5 | |
| SCHEMBL3131575 | 0.83 | TSHR (0.61) | TSHRTAS1R3TAS1R1TAS1R2ERCC5 | |
| SCHEMBL29875158 | 0.81 | CES2 (0.65) | TSHRERCC5FEN1JAK2CES2 | |
| SCHEMBL17187884 | 0.81 | CES2 (0.65) | TSHRERCC5FEN1JAK2CES2 | |
| SCHEMBL7032023 | 0.81 | TSHR (0.71) | TSHRTAS1R3TAS1R1TAS1R2ERCC5 | |
| SCHEMBL10706917 | 0.81 | TSHR (0.58) | TSHRTAS1R3TAS1R1TAS1R2ERCC5 | |
| SCHEMBL16956641 | 0.81 | TSHR (0.64) | TSHRTAS1R3TAS1R1TAS1R2ERCC5 | |
| SCHEMBL55443 | 0.81 | CES2 (0.65) | TSHRERCC5FEN1JAK2CES2 | |
| SCHEMBL706359 | 0.80 | MAPT (0.50) | TSHRTAS1R3TAS1R1TAS1R2CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 208 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110964705-A | Novel application of (R) -omega-transaminase mutant | 浙江科技学院 | 2020-04-07 | — | — | CN | claimed |
| US-8158406-B2 | reduction of keto compounds, in particular of 4-halo-3-oxobutyric acid esters, to the corresponding R-alcohols or S-4-halo-3-hydroxybutyric acid esters, respectively, using an R-specific oxidoreductase in the presence of a cofactor such as NAD(P)H | IEP GMBH (DE) | 2012-04-17 | — | — | US | claimed |
| EP-1851322-B1 | METHOD FOR THE ENANTIOSELECTIVE ENZYMATIC REDUCTION OF KETO COMPOUNDS | IEP GMBH (DE) | 2009-10-21 | — | — | EP | claimed |
| US-20080233619-A1 | Process For the Enantioselective Enzymatic Reduction of Keto Compounds | IEP GMBH (DE) | 2008-09-25 | — | — | US | claimed |
| US-20080153140-A1 | Method for the Enantioselective Enzymatic Reduction of Keto Compounds | IEP GMBH (DE) | 2008-06-26 | — | — | US | claimed |
| EP-1926821-A1 | METHOD OF ENANTIOSELECTIVE ENZYMATIC REDUCTION OF KETO COMPOUNDS | IEP GmbH (DE) | 2008-06-04 | — | — | EP | claimed |
| EP-1851322-A1 | METHOD FOR THE ENANTIOSELECTIVE ENZYMATIC REDUCTION OF KETO COMPOUNDS | IEP GmbH (DE) | 2007-11-07 | — | — | EP | claimed |
| WO-2007036257-A1 | METHOD OF ENANTIOSELECTIVE ENZYMATIC REDUCTION OF KETO COMPOUNDS | IEP GMBH (DE) | 2007-04-05 | — | — | WO | claimed |
| WO-2006087235-A1 | METHOD FOR THE ENANTIOSELECTIVE ENZYMATIC REDUCTION OF KETO COMPOUNDS | IEP GMBH (DE) | 2006-08-24 | — | — | WO | claimed |
| US-20250170141-A1 | MRGPRX2 MODULATORS AND RELATED METHODS OF TREATMENT | INCYTE CORPORATION | 2025-05-29 | — | — | US | disclosed |
| WO-2025076455-A1 | MRGPRX2 MODULATORS AND RELATED METHODS OF TREATMENT | Escient Pharmaceuticals Inc. (US) | 2025-04-10 | — | — | WO | disclosed |
| WO-2023090853-A1 | NOVEL UREA-BASED OR CARBAMATE-BASED P2X7 RECEPTOR ANTAGONIST, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING MAJOR DEPRESSIVE DISORDER, COMPRISING SAME AS ACTIVE INGREDIENT | 고려대학교 세종산학협력단 | 2023-05-25 | — | — | WO | disclosed |
| CN-110964705-A | Novel application of (R) -omega-transaminase mutant | 浙江科技学院 | 2020-04-07 | — | — | CN | disclosed |
| CN-110964705-A | Novel application of (R) -omega-transaminase mutant | 浙江科技学院 | 2020-04-07 | — | — | CN | disclosed |
| WO-1996020935-A1 | PROCESS FOR THE PREPARATION OF LAMOTRIGINE | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-07-11 | — | — | WO | disclosed |
| US-5495054-A | REDUCING PROCHIRAL KETONES TO ENANTIOMERICALLY PURE ALCOHOLS WITH BORANE REDUCING AGENT | SEPRACOR, INC. (US) | 1996-02-27 | — | — | US | disclosed |
| WO-1995032937-A1 | TETRAHYDROINDENO[1,2-d][1,3,2]OXAZABOROLES AND THEIR USE AS ENANTIOSELECTIVE CATALYSTS | SEPRACOR, INC. (US) | 1995-12-07 | — | — | WO | disclosed |
| WO-1992012959-A1 | AMIDE DERIVATIVES AND THEIR THERAPEUTIC USE | THE WELLCOME FOUNDATION LIMITED (GB) | 1992-08-06 | — | — | WO | disclosed |
| US-4326881-A | FUNGICIDES | NIPPON SODA COMPANY LIMITED (JP) | 1982-04-27 | — | — | US | disclosed |
| US-4156008-A | FUNGICIDES, BACTERICIDES | JANSSEN PHARMACEUTICA N.V. (BE) | 1979-05-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170141-A1 | MRGPRX2 MODULATORS AND RELATED METHODS OF TREATMENT | MRGPRX2, MRGPRX1, MRGPRX4 | TSHR 89/4885TAS1R3 691/4885TAS1R1 670/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.